A Phase 3, Randomized Trial of Ublituximab Plus Ibrutinib for Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukaemia

Drug Category : Array
Conference Category : Array
Lead Author : Sharman J, et al.
Published Date : 22/02/2021
Download Link : https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30433-6/fulltext
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top